Goat Anti-ELF3 / ERT/ ESX Antibody
Peptide-affinity purified goat antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | P78545 |
Other Accession | NP_004424, 1999 |
Reactivity | Human |
Host | Goat |
Clonality | Polyclonal |
Concentration | 100ug/200ul |
Isotype | IgG |
Calculated MW | 41454 Da |
Gene ID | 1999 |
---|---|
Other Names | ETS-related transcription factor Elf-3, E74-like factor 3, Epithelial-restricted with serine box, Epithelium-restricted Ets protein ESX, Epithelium-specific Ets transcription factor 1, ESE-1, ELF3 (HGNC:3318) |
Format | 0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | Goat Anti-ELF3 / ERT/ ESX Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | ELF3 (HGNC:3318) |
---|---|
Function | Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity). |
Cellular Location | Cytoplasm. Nucleus {ECO:0000255|PROSITE-ProRule:PRU00237, ECO:0000269|PubMed:10391676, ECO:0000269|PubMed:15169914, ECO:0000269|PubMed:17060315} Note=Localizes to the cytoplasm where it has been shown to transform MCF-12A mammary epithelial cells via a novel cytoplasmic mechanism Also transiently expressed and localized to the nucleus where it induces apoptosis in non-transformed breast epithelial cells MCF-10A and MCF-12A via a transcription-dependent mechanism |
Tissue Location | Expressed exclusively in tissues containing a high content of terminally differentiated epithelial cells including mammary gland, colon, trachea, kidney, prostate, uterus, stomach and skin |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Lee SH, et al. Mol Cancer Ther, 2008 Dec. PMID 19074849.
Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation. Wu J, et al. Cell Res, 2008 Jun. PMID 18475289.
ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Iwai S, et al. Oral Dis, 2008 Mar. PMID 18302674.
ESE-1 is a potent repressor of type II collagen gene (COL2A1) transcription in human chondrocytes. Peng H, et al. J Cell Physiol, 2008 May. PMID 18044710.
Toward a confocal subcellular atlas of the human proteome. Barbe L, et al. Mol Cell Proteomics, 2008 Mar. PMID 18029348.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.